Physician profile
Li Zhou
NPI 1437352895
$3,018.97
in general payments reported to CMS, 2019-2025
29 companies · $174 in 2025
The $174 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $731 · 2020: $535 · 2021: $491 · 2022: $359 · 2023: $393 · 2024: $337 · 2025: $174.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $904.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $903.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,345.28 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $217.18 | 2019-2023 | Jardiance, Stiolto Respimat, Spiriva Respimat |
| Abbvie INC. | $171.39 | 2019-2024 | Vraylar |
| Astrazeneca Pharmaceuticals LP | $128.94 | 2019-2025 | Airsupra |
| Lilly USA, LLC | $125.12 | 2019-2025 | Emgality, Reyvow, Mounjaro |
| Otsuka America Pharmaceutical, INC. | $115.64 | 2023-2025 | Rexulti |
| Abbott Laboratories | $100.57 | 2019-2021 | |
| Amarin Pharma, INC. | $79.19 | 2019-2021 | |
| Dexcom, INC. | $69.83 | 2020-2024 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $64.33 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $62.46 | 2020-2021 | |
| Phadia US INC. | $59.44 | 2021-2023 | Immunocap |
| Amgen INC. | $55.74 | 2019-2023 | Repatha, Otezla |
| Merck Sharp & Dohme LLC | $53.01 | 2019-2025 | Gardasil 9, Capvaxive |
| Shield Therapeutics INC | $50.92 | 2024 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $50.20 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $40.77 | 2022 | |
| Sanofi-Aventis U.S. LLC | $38.38 | 2019 | |
| Jazz Pharmaceuticals INC. | $30.81 | 2020 | |
| Pfizer INC. | $26.28 | 2020-2024 | |
| Gilead Sciences, INC. | $19.70 | 2020 | |
| Astellas Pharma US INC | $17.99 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.94 | 2021 | |
| Corium, LLC | $14.83 | 2023 | Azstarys |
| Teva Pharmaceuticals USA, INC. | $14.15 | 2020 | |
| Eisai INC. | $13.66 | 2024 | |
| Allergan, INC. | $13.14 | 2019 | |
| Irhythm Technologies, INC. | $12.66 | 2020 | |
| Genentech USA, INC. | $12.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Li Zhou listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.